Team

Douglass Given, MD, PhD, MBA

Doug is a physician-scientist, executive, serial entrepreneur, and investor. He is the Managing Partner at Health2047 Capital Partners LLC (HCAP) 2018-present. Doug is a founder and Chairman of Vivaldi Biosciences, Inc. Vivaldi develops genetically modified intranasal vaccines for epidemic and pandemic viral respiratory diseases. He served as Health2047 lnc. Chief Executive from its founding in 2015 until 2018. The portfolios include a dozen+ company formation startups with seed financing from Health2047 and an additional dozen+ venture investments made by HCAP. The investment themes are: data, productivity, value, and chronic disease. Doug previously spent more than two decades in venture capital as a General Partner at life sciences investor Bay City Capital, participating in five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999 to 2015. Beginning in 1983 he was a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt. As a serial entrepreneur, in addition to a number of private companies, he led three public biopharmaceutical companies as CEO. Doug has served on more than 20 public and private company boards. He currently is Chairman of Visirna Inc. (Shanghai), Chairman of Vivaldi AG (Vienna), and serves as a Director of Health2047 Inc. and BrYet Health Ltd. He is Managing Partner at the G5 Partners LLC family office. He served as Chairman of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) 2010-2024. He serves in advisory roles on the University of Chicago Pritzker School of Medicine and Biological Sciences Division Council (former Chair), and on the Health Advisory Board, Johns Hopkins Bloomberg School of Public Health. He has served on the Harvard School of Public Health HIV/AIDS Initiative and International Council, the Stanford Medicine Community Council, and advisory boards for the Stanford Institute for Economic Policy Research (SIEPR), the Houston Methodist Research Institute, the Queensland Investment Corp. (Brisbane), and InnoMed Ventures. Doug received MD and PhD (Virology) degrees from the University of Chicago and an MBA from the Wharton School at the University of Pennsylvania. He was a Clinical and Research Fellow in Internal Medicine and Infectious Diseases at Massachusetts General Hospital and Harvard Medical School, and a Professor and Attending Physician at Indiana University School of Medicine.

Katie Given, MD, PhD, MBA

Dr. Given is a physician scientist and Mohs surgeon at Palo Alto Foundation Medical Group (Sutter Health) and teaches at the UCSF/SF VA hospitals. She is board certified in Dermatology and Micrographic Surgery and Cutaneous Oncology (Mohs Surgery), and is board eligible in Clinical Informatics. She is an honors graduate from the University of Chicago and the Pritzker School of Medicine. She completed an Internal Medicine internship at the University of Chicago Hospitals, Dermatology residency at Yale-New Haven Hospitals, where she served as Chief Resident, and Mohs Surgery and Cosmetic Fellowship (injectables, lasers) at University of California, San Francisco. She received her PhD in Microbiology from the University of Chicago, Division of Biological Sciences, while performing BSL-3 select agent vaccine research and development in the Howard T Ricketts Laboratory, in partnership with the NIAID at Argonne National Laboratories. The Ricketts Lab is one of 13 regional state-of-the-art level 3 biocontainment facilities conducting research and animal studies on biodefense-related and emerging infectious diseases. Her work focused on Yersinia pestis vaccines (the causitive agent of the Black Plague), the molecular and cellular mechanisms of plague pathogenesis, Staph aureus virulence genes as targets for vaccine development, anthrax virulence factors and other bacterial and viral pathogens. In addition, she was trained to certify the workforce in BSL-3 operations. While in training, she was awarded a T32 NIH Postdoctoral Fellowship in Clinical Informatics, and worked with a Melanoma Tumor Board Registry and the Yale New Haven Hospital Center for Outcomes Research and Evaluation (CORE) focusing on database quality and validation. She is actively engaged in further development of the MohsAIQ database with the American College of Mohs Surgery (ACMS). Dr. Given served as the Resident Representative to the Board of Directors for the ASDS/ASDSA (2019-2021) and is a Contributing Editor to the peer-reviewed journal Dermatologic Surgery. Dr. Given is an active member of AAD, ASDS, ACMS and the AMA. Dr. Given received her MBA in Managerial Organization and Entrepreneurship from the University of Chicago Booth School of Business. She worked as an Innovation Fellow through the Polsky Center at UChicago, supporting faculty new business and venture formation. She served as a graduate Teaching Assistant for Booth’s renowned Commercializing Innovation curriculum. Since 2014, she has served as a partner in G5 Partners LLC. Dr. Given serves a KOL and advisor for several device and imaging companies including Avita Medical, Enspectra, Retrouvé, and Portal Instruments. Dr. Given has two sons and is an FAA-licensed pilot, with commercial, multi engine and instrument ratings.

Randy Thompson, MD

permission needed Randy has practiced medicine with Saint Luke’s Cardiovascular Consultants since 1995. His academic history spans, Emory, Massachusetts General Hospital and Harvard Medical School, and The Mayo Clinic. He is member of the Board of Directors of the American Society of Nuclear Cardiology.

Ben Lenail

Ben is a founding officer of ALD Connect, a research consortium focused on the neuro-metabolic disease X-linked adrenoleukodystrophy (X-ALD). Currently, he serves as director of business development at Alta Devices, a solar energy startup in Sunnyvale, CA.

Karl Ronn

permission needed Karl, an engineer, is the managing director of Innovation Portfolio Partners, a Silicon Valley-based firm that helps CEOs and the top management of Fortune 500 companies find and develop new-to-the-world products and services. He is on the advisory boards of Johns Hopkins Bloomberg School of Public Health, the University of Toledo, and Enviroscent.

Cindy Fong-Leeper, JD

Currently an associate general counsel at Facebook, Cindy holds a JD degree from University of Chicago Law School. Prior to joining Facebook in 2011, she served as an associate at Latham & Watkins in San Francisco and Menlo Park for seven years.